Trial · NCT01875380
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival rate at 6 months | 6 months | |
| Secondary | Objective response rate | 30 months | |
| Secondary | Disease control rate | 30 months | |
| Secondary | Time to response | 30 months | |
| Secondary | Time to progression | 30 months | |
| Secondary | Progression-free survival | 30 months | |
| Secondary | Time to treatment failure | 30 months | |
| Secondary | Response duration | 30 months | |
| Secondary | Duration of stable disease | 30 months | |
| Secondary | Overall survival | 30 months | |
| Secondary | Incidence and severity of Adverse Events (NCI CTC, version 4.0) | 30 months | |
| Secondary | Changes in laboratory values (transaminases, bilirubin, lactate dehydrogenase (LDH), anaemia,neutropenia and thrombocytopenia) | 30 months | |
| Secondary | Change in vital signs (weight loss and hypertension) | 30 months | |
| Secondary | Incidence of dose adjustments and compliance | 30 months | |
| Secondary | Incidence of concomitant medication | 30 months | |
| Secondary | Changes in ECOG performance status over time from baseline | 30 months | |
| Other | microRNA expression levels and their correlation with tumour-efficacy parameters (objective response rate, progression-free survival and overall survival), as well as toxicity | 30 months | |
| Other | Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters. | 30 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01875380/registered